US3172810A - Anti-bspkessiye n-morpholine-beta- ethylhybsazine - Google Patents
Anti-bspkessiye n-morpholine-beta- ethylhybsazine Download PDFInfo
- Publication number
- US3172810A US3172810A US3172810DA US3172810A US 3172810 A US3172810 A US 3172810A US 3172810D A US3172810D A US 3172810DA US 3172810 A US3172810 A US 3172810A
- Authority
- US
- United States
- Prior art keywords
- morpholine
- beta
- active ingredient
- hydrazine
- ethyl hydrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 description 30
- 239000003085 diluting agent Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 17
- 239000002775 capsule Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 13
- -1 heterocyclic alkyl hydrazines Chemical class 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000829 suppository Substances 0.000 description 11
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- 208000020401 Depressive disease Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000002429 hydrazines Chemical class 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008121 dextrose Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101710171573 Primary amine oxidase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000000641 cold extrusion Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 1
- 239000012493 hydrazine sulfate Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000002633 shock therapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Definitions
- this invention is concerned with pharmaceutical preparations comprising N-morpholine-beta-ethyl-hydrazine and its acid addition v salts and the use of the said preparations in the method of treating pathologic states which are affected by the monamine oxydase enzyme system.
- monamine oxdase inhibitor compounds are patterned after the structure of epinephrine (excepting the Harmala alkaloids). These compounds contain an unsaturated cyclic nucleus and an alkyl side-chain of from 2 to 4 carbons, which is substituted in the beta-position by bydrazine. This structural relationship has given rise to a postulated mechanism of activity which describes these hydrazine derivatives as pseudo-amines acting to replace the physiologically active neurohurnoral amines as an enzyme substrate. Although this mechanism of action has not been universally accepted, other investigators have confirmed the close similarity between the physiologic behavior of the amine oxydase inhibitor compounds and the naturally occurring amine enzyme substrate.
- the subject compounds of the present invention are not related to physiologically occurring stressor amine compounds and do not possess the noxious side reactions which have been described for other hydrazine derivatives, and yet are potent amine-oxidase inhibitors.
- the subject compounds of the present invention are heterocyclic derivatives comprising the heterocyclic nucleus of'morpholine to which is attached an ethyl side-chain through the nitrogen atom of the morpholine ring as well as a hydrazine group.
- N-morpholine-beta-ethyl hydrazine may be prepared through the reaction between hydrazine and N-morpholine-beta-ethyl chloride in alcoholic media.
- the compound is obtained as an oil which may be converted to a solid crystalline form by reaction with both pharmaceutically acceptable inorganic and organic acids.
- the hydrochloric acid salt of N-morpholine-beta-ethyl hydrazine is soluble in water, methanol and chloroform, but is insoluble in ether, benzene and acetone.
- the acid salts are stable and may be utilized in preparations of pharmaceutical dose forms for therapeutic use.
- N-morpholine-beta-ethyl hydrazine or its salts in therapy When it is desired to utilize N-morpholine-beta-ethyl hydrazine or its salts in therapy, it may be administered in the form of a tablet, capsule, granule or suppository in a dosage range from 1.0 to mg. per day, administered in divided doses.
- the preferred dosage is 30 to 50 mg. per day, administered in divided doses of 10 mg. each, and if more is required, an additional 20 mg. may be administered at bedtime. Improvernent should be seen within one week. After maximum benefit is attained, the dosage may be slowly reduced over a period of several weeks until a maintenance level is achieved. This maintenance level may range from 1 to 30 mg. per day, although it is preferred that the maintenance dosage be established by determining the individual requirements of the patient.
- Tablets of l -morpholine-beta-ethyl hydrazine and its salts are prepared by mixing with a pharmaceutically suitable diluent, as for example, mannitol, lactose, starch or sucrose and a lubricant such as stearic acid or magnesium stearate.
- a pharmaceutically suitable diluent as for example, mannitol, lactose, starch or sucrose and a lubricant such as stearic acid or magnesium stearate.
- the size of the tablet may range from inch in diameter to /8 inch in diameter, although the preferred tablet size is Vs inch in diameter.
- the usual ratio of the diluent to the lubricant is 50 parts diluent for each part lubricant and the range in concentration of the active ingredient in these tablets may vary from 1 mg. to 75 mg, although 10 mg. to 25 mg. is the preferred range of concentration.
- the usual ratio of diluent to active ingredient is from equal parts of diluent and active ingredient to 10 parts of diluent for each part of active ingredient.
- the active ingredient is intimately mixed with the diluent and the lubricant added.
- the mixture is granulated through a No. 60 mesh screen, utilizing a granulating solution, as for example, 50 percent alcohol-water, 1 percent gelatin solution or l percent gum arabic solution.
- the granulated mass is then dried and compressed into the proper tablet size and shape.
- Capsules are prepared by either filling a simple mixture of equal parts of active ingredient and a pharmaceutically suitable diluent, as for example, mannitol, lactose and sucrose, in a suitable hard gelatin capsule. Under certain conditions, it may be desired to dissolve the active ingredient in an inert liquid substance, as for example, cottonseed oil, and to utilize this solution to prepare liquid-filled, soft gelatin capsules. When a solid capsule s desired, the use of a lubricant may be indicated to permit rapid, automatic machine-filling or" the capsules, but this is not necessary to the manufacturing procedure when smaller lots are prepared.
- a pharmaceutically suitable diluent as for example, mannitol, lactose and sucrose
- the concentration of active ingredient in each capsule may range from 1 mg. to 75 mg. for either the solid-filled capsule or the liquid-filled capsule. It should be noted that when the lower unit dosage of acti e ingredient, as for example, between 1 mg. to 38' mg. of active ingredient is used, then larger quantities of diluent would be required for proper capsulation. In these instances, the ratio of active ingredient to diluent will vary from 200 parts diluent to 1 part active ingredient, to 3 parts diluent to 1 part active ingredient.
- granules as the dosage form, then these may be prepared by intimately combining the active ingredient with a pharmaceutically suitable diluent, as for example, mannitol, sorbitol, starch, lactose or sucrose or mixtures of these, and then granulating the mixture by passing through a screen of from. No. 8 to N 20 mesh size.
- a granulating solution such as 1 percent gurn arable, 1 percent gum tragacanth, or 2 percent gelatin solution, may be used. After drying the granulation mass the granules are screened for uniform size and filled into containers of suitable volume for dispensing. Granules are administered in teaspoonsful or tablespoonsful doses, in a unit concentration of from 1 mg. to 75 mg. of active ingredient.
- suppositories are prepared by mixing the active ingredient with a pharmaceutically suitable suppository base, as for example, cocoa butter or polyoxyethylene glycol, which are known in the trade as Carbowaxes.
- a pharmaceutically suitable suppository base as for example, cocoa butter or polyoxyethylene glycol, which are known in the trade as Carbowaxes.
- the unit weight of the suppository dose form is from 1 gm. to 3 gm. with a preferred weight of 2 gm. each.
- the concentration of active ingredient in each suppository may range from 1 mg. to '75 mg.
- Example 1 A mixture of 25 gm. of N-morpholine-be ta-ethyl hydrazine hydrochloride and 250 gm. of lactose is moistened with a 1 percent gelatin solution. The moistened mass is passed through a No. 60 mesh sieve and air dried. The dried powder is mixed with 5 gm. of magnesium stearate and the whole compressed into inch tablets, utilizing the conventional punch and die, so that each tablet contains 25 mg. of the active ingredient, N-morpholine-beta-ethyl hydrazine hydrochloride.
- the ratio of diluent to active ingredient may range from equal parts of diluent and active ingredient, to parts diluent to each part of active ingredient.
- the range in the ratio of diluent to lubricant is from 50 parts diluent to each part lubricant, to 100 parts diluent for each part lubricant.
- the range in concentration of N-morpholinebeta-ethyl hydrazine hydrochloride may vary from 1 mg. to 75 mg, per tablet, although from 10 mg. to mg. of active ingredient, per tablet, is a preferred range.
- mannitol, starch, sucrose, sorbitol and dextrose in equal parts, by weight, for the amount of lactose specified, and in place of the 1 percent gelatin solution used as a granulating agent, there may be substituted in equal parts, by weight, a percent alcohol-water solution or a 1 percent gum arabic solution or a 1 percent gum tragacanth solution.
- the amount of granulating solution is not a fixed quantity, but a sufiicient quantity to properly moisten the mass so that it will granulate upon being passed through an appropriate mesh size sieve by a process which is well known to those versed in the art of tablet manufacture.
- Example 2 in place of the N-morpholine-beta-ethyl hydrazine hydrochloride described in Example 1, above, there may be substituted in equimolecular amounts, N-morpholinebeta-ethyl hydrazine hydrobromide, N-morpholine-betaethyl hydrazine sulfate, N-morpholine-beta-ethyl hydrazine citrate, N-morpholine-beta-ethyl hydrazine tartrate, N-morpholine-beta-ethyl hydrazine succinate, N-rnorpho line-beta-ethyl hydrazine maleate and N-morpholine-betaethyl hydrazine mandelate; the remainder of the steps being the same.
- Example 3 In a glass flask containing 100 gm. of cottonseed oil, is dissolved 10 gm. of N-morpholine-beta-ethyl hydrazine with the aid of gentle heat. The cooled solution is filled into soft gelatin capsules so that each capsule contains 10 mg. of N-morpholine-beta-ethyl hydrazine per unit dose.
- any bland vegetable oil as for example, peanut oil, olive oil, safilower oil and soya bean oil, or an inert pharm aceutically acceptable liquid organic solvent, such as polyoxyethylene glycol, which is known in the trade as Carbowax, glycerin or propylene glycol.
- the usual ratio of solvent to active ingredient in preparing the liquid capsules is 10 parts solvent for each part of active ingredient, although a range of from equal parts solvent to active ingredient and 50 parts solvent to active ingredient, may be used.
- Solid capsules of N-morpholine-betaethyl hydrazine may be prepared by mixing 30 gm. of N-morpholinebeta-ethyl hydrazine with 250 gm. of an inert excipient, as for example, kaolin, and to this is added 50 gm., by Weight, of lactose. The mixture is filled into hard gelatin capsules so that each capsule contains 10 mg. of N- morpholine-beta-ethyl hydrazine per unit dose.
- an inert excipient as for example, kaolin
- Capsules of pharmaceutically acceptable salts of N- morpholine-beta-ethyl hydrazine may be prepared by fillmg into hard gelatin capsules, the dried granulation obtained as a result of the granulating steps of Examples 1 and 2, above.
- Capsules of these pharmaceutically aceptable salts of N-morpholine-beta-ethyl hydrazine may also be obtained by filling into hard gelatin capsules a mixture of equal parts of the said pharmaceutically acceptable salts of N-morpholineeta-ethyl hydrazine and a diluent selected from the group consisting of mannitol, starch, sucrose, sorbitol and dextrose.
- Example 4 Suppositories may be prepared by mixing the active ingredient, as for example, N-morpholine-beta-ethyl hydrazine and its pharmaceutically acceptable salts, with a suitable carrier, as for example, cocoa butter or the solid carbowaxes (polyoxyethylene glycol) and shaping the resultant mass into suitable suppositories which range in weight from 1 gm. to 3 gm. with a preferred Weight of 2 gm. per suppository.
- the range in concentration of active ingredient per suppository may be from 1 mg. to mg. per suppository, with 25 mg. an optimal concentration per unit dose.
- either the cold extrusion process or a hot pour molding process may be utilized.
- Example 5 Granules may be prepared by mixing 25 gm. of active ingredient, N-morpholine-beta-ethyl hydrazine with. 3 kilograms of lactose and 2 kilograms of mannitol. After thorough mixing, the mixture is moistened with a solution of 1 percent gelatin and passed through a No. 8 mesh sieve, and the granules dried. Should it be desired to flavor and color the granules, then pharmaceutically acceptable flavoring and colouring may be added.
- the concentration of active ingredient to the diluent will depend upon the unit dosage desired.
- the above formulation will permit the administration of an average dose of 25 mg. in 1 teaspoonful (5 gm.) of granules.
- tablespoonful (15 gm.) dosage be desired, then appropriate adjustment in the ratio of active ingredient to carrier is made.
- a decrease in the ratio of carrier is made.
- N-morpholine-beta-ethyl hydrazine By utilizing identical procedure and equal amounts by Weight for the N-morpholine-beta-ethyl hydrazine described above, then the pharmaceutically acceptable salts of N-morpholine-beta-ethyl hydrazine may be utilized to prepare granules for administration.
- Example 6 When it is desired to utilize N-morpholine-beta-ethyl hydrazine or its pharmaceutically acceptable salts in therapy, wherein the monamine oxydase system is involved, then these compounds may be administered in the form of a tablet, capsule, granule or suppository, in a daily dosage range of from 1 to 75 mg. per day, which is administered in divided doses. For initial treatment, the preferred dosage is 30 mg. to 50 mg, per day, which is administered in divided unit dosages of 10 mg. each. This dosage may be increased or lowered, depending upon the individual patient needs and physiologic status.
- the dibilitated geriatric patient who is chronically ill, will require less of the drug than will the average adult presenting acute symptomatology present for a short period of time.
- the child will require less than the adult, as would the patient presenting the less severe symptomatology in contrast to the more seriously ill patient.
- a daily dosage of from 1 to 26 mg. may be utilized, depending upon the degree of response of the individual patient.
- the initial physiologic response will be observed within 3 or 4 days, with improvement and relief of symptoms generally noted within 1 to 2 weeks, for the majority of the patients.
- a pharmaceutical composition in unit dosage form comprising a compatible pharmaceutical carrier and from 1 through mg. of N-morpholine-beta-ethyl hydrazine.
- a pharmaceutical composition in unit dosage form comprising a compatible pharmaceutical carrier and from 1 through 75 mg. of N-morpholine-beta-ethyl hydrazine hydrochloride.
- composition in unit dosage form comprising a compatible pharmaceutical carrier and from 1 through 75 mg. of N-morpholine-beta-ethyl hydrazine hydrobromide.
- the method of treating depressive states which comprises the steps of administering a pharmaceutical composition comprising a compound selected from the group consisting of N-morpholine-beta-ethyl hydrazine and its pharmaceutically acceptable acid addition salts, and a compatible pharmaceutical carrier.
- the method of treating depressive states which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of a compound selected from the group consisting of N-morpholine-betaethyl hydrazine and its pharmaceutically acceptable acid addition salts.
- the method of treating depressive states which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of N-morpholinebeta-ethyl hydrazine.
- the method of treating depressive states which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of N-morpholinebeta-ethyl hydrazine hydrochloride.
- the method of treating depressive states which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of N-morpholinebeta-ethyl hydrazine hydrobromide References Cited in the file of this patent UNITED STATES PATENTS 2,830,050 Biel Apr. 8, 1958 2,937,118 Haxthausen May 17, 1960 2,953,494 Cook Sept. 20, 1960 2,955,108 Omietanski Oct. 4, 1960 2,957,873 Rudner Oct. 25, 1960 2,970,145 De Benneville Jan. 31, 1961
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
United States Patent fiice.
3,172,8lh Patented Mar. 9, i965 3,1723% ANTl-DEPREEeSlVE N-MORPHGLWE-BETA- ETHYLHYDRAZENE Alfred Halpern, Great Neelr, N.Y., assignor to Synergistics, inc, New Yorlr, NY, a corporation of New York No Drawing. Filed Aug. 9, 1962, Ser. No. 215,777 8 Claims. (tCl. l6'7-e5) This invention relates to new pharmaceutical preparations of heterocyclic alkyl hydrazines and their use in the method of treating disease states relating to the monamine oxydase enzyme system. In particular, this invention is concerned with pharmaceutical preparations comprising N-morpholine-beta-ethyl-hydrazine and its acid addition v salts and the use of the said preparations in the method of treating pathologic states which are affected by the monamine oxydase enzyme system.
This application is a continuation-in-part of applicants co-pending application Serial No. 61,830, filed October 11, 1960, now United States Patent No. 3,Q86,975.
The study of the metabolism of the physiologic stressor amines (epinephrine, norephinephrine and serotonin) has shown that these substances are substrates for the monamine oxydase enzyme system. These stressor amines appear to be implicated in central nervous system and autonomic nervous system activity as well as cardiac function and to exert pronounced vascular actions and other physiologic responses.
Both monamine oxydase and its substrate are found in high levels in the hypothalamus, and it has been suggested that the amine substrate compounds play an important role in neurotransmission somewhat similar to acetylcholine. It has been postulated that certain malfunctioning of the central nervous system is due to the depletion of the neurohumoral agents by their too rapid destruction by the monamine oxydase system. Thus, for example, the therapy for true depressions has been previously limited to the replacement of these amines by the administration of central nervous system acting amine compounds (sympathomimetic amines) for the milder cases, although electroconvulsive shock therapy has been required in addition for the severe depressions when suicidal tendencies were evident.
More recently, the new therapeutic approach has been suggested which proposes to inhibit the enzymatic destruction of these stressor amines through the administration of specific chemical compounds which block the enzyme system. This blockade of the monamine oxydase system has afforded a new therapeutic horizon, offering new hope to those patients suffering from diseases caused by an imbalance of the enzyme-substrate levels, through a biochemical-physiologic approach.
There are several groups of compounds which have been shown to selectively inhibit the enzymatic action of monamine oxydase enzyme in vivo. These may be separated into two classes of compounds according to their duration of action. Those compounds exhibiting a long duration of action consist mainly of the hydrazine derivatives, and those compounds exhibiting a short duration of action consist of the Harmala alkaloids and others of differing chemical structures (such as amphetamine).
Although, for therapeutic reasons, the long-acting class of monamine oxydase inhibitors have been preferred ones, these compounds have been shown to cause serious sidereactions ranging from mild local tissue responses to death. The more commonly encountered side effects in the clinical usage of the hydrazine type of monamine oxidase inhibitors have been hypotension, anemia and liver damage. Members of the short-acting group have also been reported to cause untoward reactions which limit their therapeutic use. The need for a safe, effective means to restore the physiologic neurohumoral balance has been noted many times.
it is important to note that virtually all of the monamine oxdase inhibitor compounds are patterned after the structure of epinephrine (excepting the Harmala alkaloids). These compounds contain an unsaturated cyclic nucleus and an alkyl side-chain of from 2 to 4 carbons, which is substituted in the beta-position by bydrazine. This structural relationship has given rise to a postulated mechanism of activity which describes these hydrazine derivatives as pseudo-amines acting to replace the physiologically active neurohurnoral amines as an enzyme substrate. Although this mechanism of action has not been universally accepted, other investigators have confirmed the close similarity between the physiologic behavior of the amine oxydase inhibitor compounds and the naturally occurring amine enzyme substrate.
The subject compounds of the present invention, although hydrazine derivatives, are not related to physiologically occurring stressor amine compounds and do not possess the noxious side reactions which have been described for other hydrazine derivatives, and yet are potent amine-oxidase inhibitors. The subject compounds of the present invention are heterocyclic derivatives comprising the heterocyclic nucleus of'morpholine to which is attached an ethyl side-chain through the nitrogen atom of the morpholine ring as well as a hydrazine group.
N-morpholine-beta-ethyl hydrazine may be prepared through the reaction between hydrazine and N-morpholine-beta-ethyl chloride in alcoholic media. The compound is obtained as an oil which may be converted to a solid crystalline form by reaction with both pharmaceutically acceptable inorganic and organic acids. The hydrochloric acid salt of N-morpholine-beta-ethyl hydrazine is soluble in water, methanol and chloroform, but is insoluble in ether, benzene and acetone. The acid salts are stable and may be utilized in preparations of pharmaceutical dose forms for therapeutic use.
When it is desired to utilize N-morpholine-beta-ethyl hydrazine or its salts in therapy, it may be administered in the form of a tablet, capsule, granule or suppository in a dosage range from 1.0 to mg. per day, administered in divided doses. For initial treatment, the preferred dosage is 30 to 50 mg. per day, administered in divided doses of 10 mg. each, and if more is required, an additional 20 mg. may be administered at bedtime. Improvernent should be seen within one week. After maximum benefit is attained, the dosage may be slowly reduced over a period of several weeks until a maintenance level is achieved. This maintenance level may range from 1 to 30 mg. per day, although it is preferred that the maintenance dosage be established by determining the individual requirements of the patient.
Tablets of l -morpholine-beta-ethyl hydrazine and its salts are prepared by mixing with a pharmaceutically suitable diluent, as for example, mannitol, lactose, starch or sucrose and a lubricant such as stearic acid or magnesium stearate. The size of the tablet may range from inch in diameter to /8 inch in diameter, although the preferred tablet size is Vs inch in diameter. The usual ratio of the diluent to the lubricant is 50 parts diluent for each part lubricant and the range in concentration of the active ingredient in these tablets may vary from 1 mg. to 75 mg, although 10 mg. to 25 mg. is the preferred range of concentration. The usual ratio of diluent to active ingredient is from equal parts of diluent and active ingredient to 10 parts of diluent for each part of active ingredient. When the tablets are prepared, the active ingredient is intimately mixed with the diluent and the lubricant added. The mixture is granulated through a No. 60 mesh screen, utilizing a granulating solution, as for example, 50 percent alcohol-water, 1 percent gelatin solution or l percent gum arabic solution. The granulated mass is then dried and compressed into the proper tablet size and shape.
Capsules are prepared by either filling a simple mixture of equal parts of active ingredient and a pharmaceutically suitable diluent, as for example, mannitol, lactose and sucrose, in a suitable hard gelatin capsule. Under certain conditions, it may be desired to dissolve the active ingredient in an inert liquid substance, as for example, cottonseed oil, and to utilize this solution to prepare liquid-filled, soft gelatin capsules. When a solid capsule s desired, the use of a lubricant may be indicated to permit rapid, automatic machine-filling or" the capsules, but this is not necessary to the manufacturing procedure when smaller lots are prepared.
The concentration of active ingredient in each capsule may range from 1 mg. to 75 mg. for either the solid-filled capsule or the liquid-filled capsule. It should be noted that when the lower unit dosage of acti e ingredient, as for example, between 1 mg. to 38' mg. of active ingredient is used, then larger quantities of diluent would be required for proper capsulation. In these instances, the ratio of active ingredient to diluent will vary from 200 parts diluent to 1 part active ingredient, to 3 parts diluent to 1 part active ingredient.
When it is desired to prepare granules as the dosage form, then these may be prepared by intimately combining the active ingredient with a pharmaceutically suitable diluent, as for example, mannitol, sorbitol, starch, lactose or sucrose or mixtures of these, and then granulating the mixture by passing through a screen of from. No. 8 to N 20 mesh size. A granulating solution such as 1 percent gurn arable, 1 percent gum tragacanth, or 2 percent gelatin solution, may be used. After drying the granulation mass the granules are screened for uniform size and filled into containers of suitable volume for dispensing. Granules are administered in teaspoonsful or tablespoonsful doses, in a unit concentration of from 1 mg. to 75 mg. of active ingredient.
When the rectal route of administration is desired for these preparations then suppositories are prepared by mixing the active ingredient with a pharmaceutically suitable suppository base, as for example, cocoa butter or polyoxyethylene glycol, which are known in the trade as Carbowaxes. The unit weight of the suppository dose form is from 1 gm. to 3 gm. with a preferred weight of 2 gm. each. The concentration of active ingredient in each suppository may range from 1 mg. to '75 mg.
The following examples illustrate the subject compounds of the present invention.
Example 1 A mixture of 25 gm. of N-morpholine-be ta-ethyl hydrazine hydrochloride and 250 gm. of lactose is moistened with a 1 percent gelatin solution. The moistened mass is passed through a No. 60 mesh sieve and air dried. The dried powder is mixed with 5 gm. of magnesium stearate and the whole compressed into inch tablets, utilizing the conventional punch and die, so that each tablet contains 25 mg. of the active ingredient, N-morpholine-beta-ethyl hydrazine hydrochloride.
The ratio of diluent to active ingredient may range from equal parts of diluent and active ingredient, to parts diluent to each part of active ingredient. The range in the ratio of diluent to lubricant is from 50 parts diluent to each part lubricant, to 100 parts diluent for each part lubricant. The range in concentration of N-morpholinebeta-ethyl hydrazine hydrochloride may vary from 1 mg. to 75 mg, per tablet, although from 10 mg. to mg. of active ingredient, per tablet, is a preferred range.
In place of the lactose utilized above, there may be substituted mannitol, starch, sucrose, sorbitol and dextrose in equal parts, by weight, for the amount of lactose specified, and in place of the 1 percent gelatin solution used as a granulating agent, there may be substituted in equal parts, by weight, a percent alcohol-water solution or a 1 percent gum arabic solution or a 1 percent gum tragacanth solution. It should be noted that the amount of granulating solution is not a fixed quantity, but a sufiicient quantity to properly moisten the mass so that it will granulate upon being passed through an appropriate mesh size sieve by a process which is well known to those versed in the art of tablet manufacture.
Example 2 in place of the N-morpholine-beta-ethyl hydrazine hydrochloride described in Example 1, above, there may be substituted in equimolecular amounts, N-morpholinebeta-ethyl hydrazine hydrobromide, N-morpholine-betaethyl hydrazine sulfate, N-morpholine-beta-ethyl hydrazine citrate, N-morpholine-beta-ethyl hydrazine tartrate, N-morpholine-beta-ethyl hydrazine succinate, N-rnorpho line-beta-ethyl hydrazine maleate and N-morpholine-betaethyl hydrazine mandelate; the remainder of the steps being the same.
Example 3 In a glass flask containing 100 gm. of cottonseed oil, is dissolved 10 gm. of N-morpholine-beta-ethyl hydrazine with the aid of gentle heat. The cooled solution is filled into soft gelatin capsules so that each capsule contains 10 mg. of N-morpholine-beta-ethyl hydrazine per unit dose.
In place of the cottonseed oil used as a solvent, there may be substituted, in equal weight, any bland vegetable oil, as for example, peanut oil, olive oil, safilower oil and soya bean oil, or an inert pharm aceutically acceptable liquid organic solvent, such as polyoxyethylene glycol, which is known in the trade as Carbowax, glycerin or propylene glycol. The usual ratio of solvent to active ingredient in preparing the liquid capsules is 10 parts solvent for each part of active ingredient, although a range of from equal parts solvent to active ingredient and 50 parts solvent to active ingredient, may be used.
Solid capsules of N-morpholine-betaethyl hydrazine may be prepared by mixing 30 gm. of N-morpholinebeta-ethyl hydrazine with 250 gm. of an inert excipient, as for example, kaolin, and to this is added 50 gm., by Weight, of lactose. The mixture is filled into hard gelatin capsules so that each capsule contains 10 mg. of N- morpholine-beta-ethyl hydrazine per unit dose.
Capsules of pharmaceutically acceptable salts of N- morpholine-beta-ethyl hydrazine may be prepared by fillmg into hard gelatin capsules, the dried granulation obtained as a result of the granulating steps of Examples 1 and 2, above. Capsules of these pharmaceutically aceptable salts of N-morpholine-beta-ethyl hydrazine may also be obtained by filling into hard gelatin capsules a mixture of equal parts of the said pharmaceutically acceptable salts of N-morpholineeta-ethyl hydrazine and a diluent selected from the group consisting of mannitol, starch, sucrose, sorbitol and dextrose.
Example 4 Suppositories may be prepared by mixing the active ingredient, as for example, N-morpholine-beta-ethyl hydrazine and its pharmaceutically acceptable salts, with a suitable carrier, as for example, cocoa butter or the solid carbowaxes (polyoxyethylene glycol) and shaping the resultant mass into suitable suppositories which range in weight from 1 gm. to 3 gm. with a preferred Weight of 2 gm. per suppository. The range in concentration of active ingredient per suppository may be from 1 mg. to mg. per suppository, with 25 mg. an optimal concentration per unit dose. In preparing the suppositories, either the cold extrusion process or a hot pour molding process may be utilized.
Example 5 Granules may be prepared by mixing 25 gm. of active ingredient, N-morpholine-beta-ethyl hydrazine with. 3 kilograms of lactose and 2 kilograms of mannitol. After thorough mixing, the mixture is moistened with a solution of 1 percent gelatin and passed through a No. 8 mesh sieve, and the granules dried. Should it be desired to flavor and color the granules, then pharmaceutically acceptable flavoring and colouring may be added.
The concentration of active ingredient to the diluent will depend upon the unit dosage desired. Thus, the above formulation will permit the administration of an average dose of 25 mg. in 1 teaspoonful (5 gm.) of granules. Should larger quantities, as for example, tablespoonful (15 gm.) dosage be desired, then appropriate adjustment in the ratio of active ingredient to carrier is made. Similarly, when smaller unit dosages, as for example, one-half teaspoonful are desired, a decrease in the ratio of carrier is made.
By utilizing identical procedure and equal amounts by Weight for the N-morpholine-beta-ethyl hydrazine described above, then the pharmaceutically acceptable salts of N-morpholine-beta-ethyl hydrazine may be utilized to prepare granules for administration.
Example 6 When it is desired to utilize N-morpholine-beta-ethyl hydrazine or its pharmaceutically acceptable salts in therapy, wherein the monamine oxydase system is involved, then these compounds may be administered in the form of a tablet, capsule, granule or suppository, in a daily dosage range of from 1 to 75 mg. per day, which is administered in divided doses. For initial treatment, the preferred dosage is 30 mg. to 50 mg, per day, which is administered in divided unit dosages of 10 mg. each. This dosage may be increased or lowered, depending upon the individual patient needs and physiologic status. Thus, the dibilitated geriatric patient, who is chronically ill, will require less of the drug than will the average adult presenting acute symptomatology present for a short period of time. Similarly, the child will require less than the adult, as would the patient presenting the less severe symptomatology in contrast to the more seriously ill patient.
For maintenance therapy, a daily dosage of from 1 to 26 mg. may be utilized, depending upon the degree of response of the individual patient.
The initial physiologic response will be observed within 3 or 4 days, with improvement and relief of symptoms generally noted within 1 to 2 weeks, for the majority of the patients.
It is not desired to be limited except as set forth in the following claims, the above description being by way of illustration of the invention.
What is claimed is:
1. A pharmaceutical composition in unit dosage form comprising a compatible pharmaceutical carrier and from 1 through mg. of N-morpholine-beta-ethyl hydrazine.
2. A pharmaceutical composition in unit dosage form comprising a compatible pharmaceutical carrier and from 1 through 75 mg. of N-morpholine-beta-ethyl hydrazine hydrochloride.
3.A pharmaceutical composition in unit dosage form comprising a compatible pharmaceutical carrier and from 1 through 75 mg. of N-morpholine-beta-ethyl hydrazine hydrobromide.
4. The method of treating depressive states which comprises the steps of administering a pharmaceutical composition comprising a compound selected from the group consisting of N-morpholine-beta-ethyl hydrazine and its pharmaceutically acceptable acid addition salts, and a compatible pharmaceutical carrier.
5. The method of treating depressive states, which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of a compound selected from the group consisting of N-morpholine-betaethyl hydrazine and its pharmaceutically acceptable acid addition salts.
6. The method of treating depressive states, which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of N-morpholinebeta-ethyl hydrazine.
7. The method of treating depressive states, which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of N-morpholinebeta-ethyl hydrazine hydrochloride.
8. The method of treating depressive states, which comprises the step of administering in unit dosage form a pharmaceutical composition comprising a pharmaceutical carrier and from 1 through 75 mg. of N-morpholinebeta-ethyl hydrazine hydrobromide References Cited in the file of this patent UNITED STATES PATENTS 2,830,050 Biel Apr. 8, 1958 2,937,118 Haxthausen May 17, 1960 2,953,494 Cook Sept. 20, 1960 2,955,108 Omietanski Oct. 4, 1960 2,957,873 Rudner Oct. 25, 1960 2,970,145 De Benneville Jan. 31, 1961
Claims (1)
1. A PHARMACEUTICAL COMPOSITION IN UNIT DOSAGE FORM COMPRISING A COMPATIBLE PHARMACEUTICAL CARRIER AND FROM 1 THROUGH 75 MG. OF N-MORPHOLINE-BETA-ETHYL HYDRAZINE.
Publications (1)
Publication Number | Publication Date |
---|---|
US3172810A true US3172810A (en) | 1965-03-09 |
Family
ID=3457184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US3172810D Expired - Lifetime US3172810A (en) | Anti-bspkessiye n-morpholine-beta- ethylhybsazine |
Country Status (1)
Country | Link |
---|---|
US (1) | US3172810A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830050A (en) * | 1955-02-15 | 1958-04-08 | Lakeside Lab Inc | Symmetrical substituted aminoalkylhydrazines and their salts |
US2937118A (en) * | 1956-06-27 | 1960-05-17 | Raschig Gmbh Dr F | Aminopyridine compositions |
US2953494A (en) * | 1957-07-15 | 1960-09-20 | Smith Kline French Lab | 2-amino-1-(3, 4-methylenedioxyphenyl)-propane isomers, ataractic preparation containing 2-amino-1-(3, 4-methylenedioxyphenyl)-propane and method of producing ataraxia |
US2955108A (en) * | 1957-01-07 | 1960-10-04 | Univ Ohio State Res Found | Process for 1,1,1-trisubstituted hydrazinium chlorides |
US2957873A (en) * | 1958-08-04 | 1960-10-25 | Grace W R & Co | Aralkylhydrazinium salts |
US2970145A (en) * | 1957-12-23 | 1961-01-31 | Rohm & Haas | Aminoacetamidoximic quaternary ammonium compounds |
-
0
- US US3172810D patent/US3172810A/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830050A (en) * | 1955-02-15 | 1958-04-08 | Lakeside Lab Inc | Symmetrical substituted aminoalkylhydrazines and their salts |
US2937118A (en) * | 1956-06-27 | 1960-05-17 | Raschig Gmbh Dr F | Aminopyridine compositions |
US2955108A (en) * | 1957-01-07 | 1960-10-04 | Univ Ohio State Res Found | Process for 1,1,1-trisubstituted hydrazinium chlorides |
US2953494A (en) * | 1957-07-15 | 1960-09-20 | Smith Kline French Lab | 2-amino-1-(3, 4-methylenedioxyphenyl)-propane isomers, ataractic preparation containing 2-amino-1-(3, 4-methylenedioxyphenyl)-propane and method of producing ataraxia |
US2970145A (en) * | 1957-12-23 | 1961-01-31 | Rohm & Haas | Aminoacetamidoximic quaternary ammonium compounds |
US2957873A (en) * | 1958-08-04 | 1960-10-25 | Grace W R & Co | Aralkylhydrazinium salts |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5925323A (en) | Depression disease parkinsonism therapy made from pterin derivative | |
EP1702612B1 (en) | Soft capsule containing butylphthalide and its preparation procedure | |
Kragh-Sorensen et al. | Plasma levels of nortriptyline in the treatment of endogenous depression. | |
CZ282679B6 (en) | The use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole for preparing a pharmaceutical preparation | |
JPH07300417A (en) | Antidepressant or anti-parkinsonism medicine | |
EP0146363A2 (en) | Synergistic pharmaceutical compositions, their production and use | |
US3954988A (en) | Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects | |
US4331687A (en) | Treatment of Parkinson's disease | |
US3172810A (en) | Anti-bspkessiye n-morpholine-beta- ethylhybsazine | |
EP1655029B1 (en) | Medicinal compositions | |
KR20050009983A (en) | Sustained release formulation of tramadol | |
JPS61183225A (en) | Medicinal composition containing 9,10- dihydroergot alkaloid | |
US4206214A (en) | Antithrombotic pharmaceutical compositions containing dipyridamole and sulfinpyrazone | |
JPS5815915A (en) | Antiobesity drug | |
JP2540871B2 (en) | Antihyperlipidemic agent | |
DE4009941A1 (en) | Use of pteridine(s) to sensitise resistant plasmodia - in combination with conventional di:hydro:folate reductase inhibitors and di:hydro-pteroate synthase inhibitors | |
US4017614A (en) | Compositions for the relief of migraine | |
US2910403A (en) | Anti hypertensive compositions comprising 2-methyl-5, 8-dimethoxychromone and acetamides | |
US20050069584A1 (en) | Diphenhydramine tannate solid dose compositions and methods of use | |
US3624203A (en) | Pharmaceutical contraceptive preparation | |
US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
US3422191A (en) | Compositions and methods for tranquilization employing salts of n-morpholine ethanol | |
US3086975A (en) | Nu-morpholine-beta-ethyl hydrazine and acid addition salts thereof | |
KR100366233B1 (en) | Miscible composition containing extract of black cohosh | |
US3152045A (en) | Composition and method for angina pectoris therapy |